BVXV
BiondVax Pharmaceuticals Ltd. [BVXV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BVXV Stock Summary
In the News
BVXV Financial details
Company Rating
-
Market Cap
4.97M
Income
7.78M
Revenue
2.02M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
29 Nov 2023
P/E
0.59
Forward P/E
-
PEG
-0.05
P/S
2.46
P/B
-0.65
P/C
-
P/FCF
-3.53
Quick Ratio
4.05
Current Ratio
4.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
2.94
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-6.72%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
39%
ROE
-720%
ROC
-0.48%
Gross Margin
100%
Oper. Margin
-432%
Profit Margin
386%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.63-11.49
52W High
-
52W Low
-
RSI
-
Rel Volume
0.58
Avg Volume
38.94K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.36618
-
-
Volatility
0.26%, 0.26%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 38.94K
- Market Capitalization 4.97M
- Employee 33
- CEO Mr. Amir Reichman M.B.A., M.Sc.
- Headquarters Jerusalem,IL
- IPO Date 2015-05-12
-
Website
https://www.biondvax.com 
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
